Overview

A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia

Status:
RECRUITING

Trial end date:
2027-06-01

Target enrollment:

Participant gender:

Summary

The researchers are doing this study to find out if an allogeneic hematopoietic stem cell transplant (HSCT) or maintenance therapy with azacitidine and venetoclax is more effective at keeping AML from coming back (relapsing).

Phase:

PHASE2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborator:

Genentech, Inc.

Treatments:

Azacitidine
venetoclax